hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06295016 id: NYCU112130AE briefTitle: Stressors and Recovery Regulation on the Super-compensation Effect overallStatus: RECRUITING date: 2023-09-01 date: 2024-08-31 date: 2025-08-31 date: 2024-03-06 date: 2024-03-06 name: National Yang Ming University class: OTHER briefSummary: Purpose: Investigating the effects of stressors and recovery regulation on the super-compensation effect of high-intensity intensive training (IT) in endurance athletes. Methods: This study will recruit 176 competitively trained endurance adult athletes. Participants will conduct a 7-week 3-stage experiment, including 3 weeks of regular training, 3 weeks of 130% progressive IT, and 1 week of 55% taper. Measurement will include training responses (performance and fatigue symptoms), stressors, recovery regulation, and mood state at baseline, during and after regular training, IT, and taper separately. According to the performance after taper, all participants will category into either the responder or non-responder of well-response to supercompensation effect. Statistic analysis: Independent t-test, Chi-squared test, and binary logistic regression will be used to compare the difference in training responses, stressors, recovery regulation, and mood state characteristics between responder and non-responder groups. P value sets at 0.15 for identifying the potential predictors. Logistic stepwise multiple regression will be used further to determine the significant predictors for the responders of well-response to the super-compensation among endurance athletes. P value sets at 0.05. conditions: Exercise Overtraining conditions: Stressor, Psychological studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: SINGLE_GROUP interventionModelDescription: The present study is designed as a prospective intervention and prognostic prediction study, employing a single-subject design with a reversal (ABA) design. This design involves a self-controlled intervention experiment with three phases: baseline training period (A), high-intensity, high-volume training period (B), and reduced training period (A). Subsequently, the study aims to explore predictive factors influencing the presence or absence of favorable compensatory training effects following the intervention. primaryPurpose: SCREENING masking: DOUBLE maskingDescription: Prior to the commencement of the experiment and during the experimental period, both the participants and the investigator will be unaware of whether the participants exhibit a good response to compensatory training effects. After the participants complete the entire experimental procedure, they will be grouped post hoc based on their outcomes following the intervention, according to predetermined criteria.
2. Response group: Exercise performance during the tapering period (week 7) shows a significant increase compared to post-intervention (week 6) and is higher than the change in exercise performance during normal training (= week 3 - week 1). whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 158 type: ESTIMATED name: High-intensity intensive training name: Taper measure: Stressor measure: Recovery regulation measure: Mood state measure: Peak power output measure: Maximal heart rate measure: Fatigue state sex: ALL minimumAge: 18 Years maximumAge: 50 Years stdAges: ADULT facility: Department of Physical Therapy and Assistive Technology, National Yang Ming Chiao Tung University status: RECRUITING city: Taipei zip: 112304 country: Taiwan name: Wei-Wun Tsai role: CONTACT phone: +886-02-2826-7939 email: tmwk@nycu.edu.tw lat: 25.04776 lon: 121.53185 hasResults: False
nctId: NCT06295003 id: CEFA-COVID briefTitle: Impact of COVID-19 Pandemic on Headache Evaluations in the Pediatric Emergency Department overallStatus: COMPLETED date: 2022-04-30 date: 2022-05-30 date: 2022-05-30 date: 2024-03-06 date: 2024-03-06 name: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico class: OTHER briefSummary: Background: To evaluate the impact of COVID-19 on evaluations in the pediatric emergency department (ED) because of headache as main symptom.
Methods: Number and clinical features of patients evaluated in the pediatric ED of a single site in Milan,Italy, were collected between January 2017 and January 2022. The impact of COVID-19 on evaluation rates was quantified by using the incidence rate ratio (IRR) and 95% confidence intervals (CI) between the pandemic (March 2020 to January 2022) and the prepandemic period (January 2017 to February 2020). conditions: COVID-19 conditions: Headache Disorders conditions: Emergency Service, Hospital studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 700 type: ACTUAL measure: During the study period, 890 evaluations were registered: the number of partecipants was 689 over the prepandemic period and 201 over the pandemic period. Mean age at evaluation was 10 years (range: 1 to 17 years). measure: Evaluation rates per month were 18.1 during the prepandemic period and 8.7 during COVID-19 pandemic, with peaks in autumn and winter and drops in summer. The reduction in evaluation rate was higher for secondary headache when compared with primary one sex: ALL minimumAge: 2 Years maximumAge: 18 Years stdAges: CHILD stdAges: ADULT facility: Pediatric Emergency Department Clinica de Marchi, Foundation IRCCS Ca' Granda, Ospedale Maggiore Policlinico city: Milan country: Italy lat: 45.46427 lon: 9.18951 hasResults: False
nctId: NCT06294990 id: 2023-505854-16-00 briefTitle: Klinefelter Syndrome and Testosterone Treatment in Puberty acronym: TiPY overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2029-12-31 date: 2029-12-31 date: 2024-03-06 date: 2024-03-06 name: Lise Aksglæde class: OTHER briefSummary: The goal of this randomized clinical trial is to study the effect of testosterone replacement therapy during puberty in boys with Klinefelter syndrome (KS, 47,XXY).
Participants will be randomized to two years treatment with testosterone or placebo. conditions: Klinefelter Syndrome studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Multi-center, national, randomized, double-blind, placebo-controlled intervention study primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 32 type: ESTIMATED name: Testosterone gel name: Placebo measure: Changes in body fat mass measure: Pubertal development and virilization measure: Height measure: Weight measure: Bone mineralization measure: Neuropsychological evaluation measure: Neuropsychological evaluation, sex: MALE minimumAge: 10 Years maximumAge: 14 Years stdAges: CHILD hasResults: False
nctId: NCT06294977 id: CRISI-COVID briefTitle: Impact of COVID-19 Pandemic on Epilepsy Evaluations in the Pediatric Emergency Department overallStatus: COMPLETED date: 2022-11-30 date: 2022-12-30 date: 2022-12-30 date: 2024-03-06 date: 2024-03-06 name: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico class: OTHER briefSummary: Background. Seizures are a common cause of evaluation in the pediatric emergency department (ED). Several studies about the impact of COVID-19 pandemic on ED attendances report a considerable reduction in general pediatric care. The aim of our study was to evaluate the impact of COVID-19 on the admission to the pediatric ED for seizures.
Materials and methods. We performed a retrospective study to assess the rate of ED admission for seizures at the pediatric ED of the Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico of Milan between January 2017 and December 2021, comparing the pre-pandemic (from January 2017 to February 2020) and pandemic periods (from March 2020 to December 2021). conditions: Epilepsy conditions: Emergency Services, Hospital conditions: COVID-19 studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 1000 type: ACTUAL measure: During the study period, 1,091 patients with seizures were admitted to pediatric ED, 776 before the pandemic and 315 during the pandemic. In particular, the evaluation rates per month were 20.4 before the pandemic and 14.3 afterward measure: Patients with a history of previous seizures showed a greater decrease in the monthly number of ED visits compared to those with a first seizure. An increased rate of unprovoked seizures and a decreased rate of provoked ones were observed in the pandemic sex: ALL minimumAge: 1 Month maximumAge: 17 Years stdAges: CHILD facility: Pediatric Emergency Department Clinica de Marchi, Foundation IRCCS Ca' Granda, Ospedale Maggiore Policlinico city: Milan country: Italy lat: 45.46427 lon: 9.18951 hasResults: False
nctId: NCT06294964 id: Sleep Education briefTitle: Intervention and Effect of Sleep Pattern on Cardio-cerebrovascular Disease overallStatus: ENROLLING_BY_INVITATION date: 2024-03-01 date: 2025-06-01 date: 2026-11-30 date: 2024-03-06 date: 2024-03-06 name: RenJi Hospital class: OTHER briefSummary: Because of the growing population of older people, cardio-cerebrovascular diseases has been the most important aging-related chronic disease, studying the pathogenesis and early warning mechanisms of cardio-cerebrovascular diseases in depth, exploring optimal strategies for early diagnosis and treatments of cardio-cerebrovascular diseases has becoming the urgent public health problem in China. Aging causes cellular changes that change the sleep status in older adults, leading to an increased risk of disease and death. Meanwhile, the rising prevalence of chronic diseases among older adults also increases the impact of sleep deprivation. Insufficient sleep has being a serious challenge to the health status of the elderly. However, there is no clinically significant treatment for sleep disorders caused by chronic diseases. Medication helps to sleep but will also lead to drug dependence and increasing the risk of recurrent sleep disorders, which is unfavorable for disease control.
Therefore, on the basis of the established Pudong community cohort, the project applicant led the team to adopt an open-label, blind endpoint, and cluster-randomized two-phase trial method to randomly assign cohort members into intervention group and control group. According to the sleep health intervention plan formulated by the clinical team, family doctor provides health education materials according to the actual situation of the intervention group regularly. Family doctors in the control group used conventional management methods. The final assessment was that compared to control group, whether the intervention group improved members' sleep quality, reduced members' cardiovascular disease events, and individual cardiovascular disease morbidity and all-cause mortality during the study period. conditions: Cardiovascular Diseases conditions: Non-Communicable Chronic Diseases studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: NONE count: 12800 type: ESTIMATED name: sleep education, behavioral education measure: the incidence and/or prevalence of cardiovascular diseases such as myocardial infarction, stroke, heart failure, and cardiovascular death measure: all cause death sex: ALL minimumAge: 60 Years maximumAge: 120 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Cardiology, Ren Ji Hospital city: Shanghai country: China lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06294951 id: IIT-2023-0225 briefTitle: fMRI for BPS: A Descriptive Study of Findings and Symptoms overallStatus: RECRUITING date: 2024-03-01 date: 2026-12-31 date: 2026-12-31 date: 2024-03-06 date: 2024-03-06 name: RenJi Hospital class: OTHER briefSummary: The goal of this observational study is to investigate the relationship between functional magnetic resonance imaging (fMRI) findings of the brain and symptom presentation in patients with bladder pain syndrome (BPS). The main questions it aims to answer are:
Participants will undergo fMRI as well as other routine laboratory tests and queries. conditions: Bladder Pain Syndrome studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: OTHER count: 120 type: ESTIMATED name: fMRI measure: fMRI findings sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Renji Hospital, Shanghai Jiao Tong University School of Medicine status: RECRUITING city: Shanghai state: Shanghai zip: 200127 country: China name: Zhebin Du, Dr. role: CONTACT phone: +86-13512179027 email: Dzbdzb1989@163.com name: Zhebin Du, Dr. role: PRINCIPAL_INVESTIGATOR name: Yinghui Fan, Dr. role: PRINCIPAL_INVESTIGATOR name: Yingfu Jiao, Dr. role: SUB_INVESTIGATOR name: Liang Dong, Dr. role: SUB_INVESTIGATOR name: Qixiang Song, Dr. role: SUB_INVESTIGATOR name: Xinxing Du, Dr. role: SUB_INVESTIGATOR name: Yanhao Dong, Dr. role: SUB_INVESTIGATOR lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06294938 id: M.WRI-2023-INQ-2224 briefTitle: Glycemic Index of Cacao Fruit Pulp in Healthy, Human Subjects overallStatus: COMPLETED date: 2022-09-30 date: 2023-01-24 date: 2023-05-23 date: 2024-03-06 date: 2024-03-06 name: Mars Wrigley class: INDUSTRY name: INQUIS Clinical Research briefSummary: Cacao fruit pulp is a sweet and fruity carbohydrate-rich edible mucilage that is often discarded. The objective of this study is to assess the glycemic response and determine the glycemic index of cacao fruit pulp. conditions: Blood Sugar; High conditions: Blood Sugar; Low studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: acute, open-labeled, randomized design primaryPurpose: BASIC_SCIENCE masking: NONE count: 10 type: ACTUAL name: Cacao fruit pulp name: Dextrose measure: Plasma Glucose measure: Incremental area under the curve measure: Peak plasma glucose sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: INQUIS Clinical Research city: Toronto state: Onterio zip: M5C 2N8 country: Canada lat: 43.70011 lon: -79.4163 hasResults: False
nctId: NCT06294925 id: C5041041 id: EFFECT-UC type: OTHER domain: Alias Study Number briefTitle: A Study to Learn About the Effectiveness of Etrasimod in People With Ulcerative Colitis acronym: EFFECT-UC overallStatus: NOT_YET_RECRUITING date: 2024-04-20 date: 2027-04-01 date: 2027-04-20 date: 2024-03-06 date: 2024-03-06 name: Pfizer class: INDUSTRY briefSummary: The purpose of this real world non-interventional study is to learn about the effects of etrasimod as treatment for patients with moderate to severe ulcerative colitis.
The effects of etrasimod will be analyzed for each patient comparing to their disease activity prior to the start of etrasimod. conditions: Colitis, Ulcerative studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 260 type: ESTIMATED name: Etrasimod measure: Proportion of patients with symptomatic remission measure: Proportion of patients with symptomatic remission measure: Proportion of patients with clinical response measure: Proportion of patients with clinical response. measure: Proportion of corticosteroid-free patients with symptomatic remission sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06294912 id: 7602-003 id: MK-7602-003 type: OTHER domain: Merck briefTitle: A Study to Evaluate Antimalarial Activity and Safety of MK-7602 in Healthy Adults (MK-7602-003) overallStatus: NOT_YET_RECRUITING date: 2024-04-02 date: 2025-03-10 date: 2025-03-10 date: 2024-03-06 date: 2024-03-06 name: Merck Sharp & Dohme LLC class: INDUSTRY briefSummary: The purpose of this study is to assess the antimalarial activity, pharmacokinetics, and safety of MK-7602 in healthy adults following Plasmodium falciparum (P. falciparum) infection. conditions: Malaria studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: NONE count: 42 type: ESTIMATED name: Plasmodium falciparum name: MK-7602 name: Artemether/lumefantrine name: Primaquine name: Artesunate name: Atovaquone/proguanil measure: Parasite reduction ratio (PRR48) (Parts 1 and 2) measure: Parasite Clearance Half-life (PCt1/2) (Parts 1 and 2) measure: Parasite Regrowth (Parts 1 and 2) measure: Part 1 Single dose: Area Under the Concentration-Time Curve Extrapolated to Infinity (AUC0-inf) of MK-7602 measure: Part 1 Single dose: Maximum Plasma Concentration (Cmax) of MK-7602 measure: Part 1 Single dose: Concentration at 24 Hours (C24) of MK-7602 measure: Part 1 Single dose: Time to Maximum Plasma Concentration (Tmax) of MK-7602 measure: Part 1 Single dose: Elimination Half-life (t1/2) of MK-7602 measure: Part 2 Multiple dose: Area Under the Curve Time 0 to End of the Dosing Interval (AUC0-tau) of MK-7602 measure: Part 2 Multiple dose: Maximum Plasma Concentration (Cmax) of MK-7602 measure: Part 2 Multiple dose: Time to Maximum Plasma Concentration (Tmax) of MK-7602 measure: Part 2 Multiple dose: Elimination Half-life (t1/2) of MK-7602 measure: Number of Participants Who Experience an Adverse Event (AE) measure: Number of Participants Who Discontinue Study Intervention Due to an AE sex: ALL minimumAge: 18 Years maximumAge: 55 Years stdAges: ADULT hasResults: False
nctId: NCT06294899 id: 23/222-P briefTitle: CRP and Lung Ultrasound in Respiratory Evaluation acronym: PLURE overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2025-05-30 date: 2028-09-01 date: 2024-03-06 date: 2024-03-06 name: Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina class: OTHER briefSummary: Lower respiratory tract infections (LRTIs) are one of the most common reasons for consultation in Primary Care centres. Differentiating between viral and bacterial aetiologies can be challenging, leading to inappropriate antibiotic prescribing. Lung ultrasound (LUS), an imaging test that gained particular relevance since the beginning of the SARS-CoV-2 pandemic, offers several advantages over the classic chest X-ray in detecting and monitoring LRTIs, especially when pleural involvement exists.
This study aims to correlate LUS findings with capillary blood C-Reactive Protein (CRP) values in patients with LRTIs, evaluating LUS as a diagnostic tool and its impact on therapeutic decisions. The descriptive observational study, conducted from January 2024 to December 2026 in Lleida, will include LRTI patients attending Primary Care centres. By validating LUS as a rapid and non-invasive diagnostic tool, unnecessary antibiotic prescriptions can be reduced, promoting LUS as a complementary test in Primary Care consultations. This will facilitate appropriate diagnosis and treatment decisions for patients with LRTIs, enhancing the overall management of respiratory infections. conditions: C-Reactive Protein conditions: Ultrasonography conditions: Primary Health Care conditions: Lower Respiratory Tract Infection studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: PROSPECTIVE count: 202 type: ESTIMATED name: Lung ultrasound measure: Ultrasound patterns measure: C-Reactive Protein sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06294886 id: Innovis RD-2401 briefTitle: Vaginal Fluid Collection for Detection of Endometrial Cancer overallStatus: RECRUITING date: 2024-02-19 date: 2024-06-01 date: 2024-06-01 date: 2024-03-06 date: 2024-03-07 name: Innovis LLC class: INDUSTRY briefSummary: The primary objective of this study is to obtain de-identified vaginal fluid specimens from participants with an endometrial tissue biopsy-based histopathological diagnosis of endometrial cancer (EC), endometrial hyperplasia (AEH) with atypia or endometrial intraepithelial neoplasia (EIN).
The samples will be used for the purpose of research and development of a new molecular diagnostic test for the detection of EC, AEH and EIN. conditions: Endometrial Cancer studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 40 type: ESTIMATED name: Screening test to detect endometrial cancer and precancer measure: Detection of endometrial cancer and precancer sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Trials365 status: RECRUITING city: Shreveport state: Louisiana zip: 71118 country: United States name: Jen Cory role: CONTACT phone: 318-408-1198 email: j.cory@trials365.org name: Destin Black, MD role: PRINCIPAL_INVESTIGATOR lat: 32.52515 lon: -93.75018 hasResults: False
nctId: NCT06294873 id: Innovis RD-2301 briefTitle: Stool Sample Collection Study overallStatus: RECRUITING date: 2023-07-20 date: 2024-04-30 date: 2024-04-30 date: 2024-03-06 date: 2024-03-06 name: Innovis LLC class: INDUSTRY name: Exact Sciences Corporation briefSummary: The primary objective of this study is to obtain de-identified stool specimens from participants with colonoscopic biopsy-based histopathologic diagnosis of colorectal cancer (CRC) and/or a ≥1 cm colorectal polyp/adenoma/mass found during pre-enrollment colonoscopy that is of sufficient size to require surgical excision or complex colonoscopic polypectomy.
The samples will be used for the purpose of research and development of a new molecular diagnostic test for the detection of neoplasms of the aerodigestive tract. conditions: Colorectal Cancer studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 40 type: ESTIMATED name: A screening device for the detection of colorectal and other aerodigestive tract cancers measure: Detection of colon cancer or precancer sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Associated Gastroenterology Medical Group status: RECRUITING city: Anaheim state: California zip: 92810 country: United States name: Brian Riff, MD role: CONTACT phone: 714-778-1300 phoneExt: 227 email: briff@agmg.com name: Brian Riff, MD role: PRINCIPAL_INVESTIGATOR lat: 33.83529 lon: -117.9145 facility: Sarkis Clinical Trials status: RECRUITING city: Ocala state: Florida zip: 34474 country: United States name: Jen Corcoran role: CONTACT phone: 352-363-5395 phoneExt: 272 email: merci@ehsfamily.com name: Vishnu Reddy, MD role: PRINCIPAL_INVESTIGATOR lat: 29.1872 lon: -82.14009 facility: Gastro One status: RECRUITING city: Cordova state: Tennessee zip: 38018 country: United States name: Brian Dragutsky role: CONTACT phone: 901-606-8924 email: brian.dragutsky@onegi.com name: Ziad Younes, MD role: PRINCIPAL_INVESTIGATOR lat: 35.15565 lon: -89.7762 hasResults: False
nctId: NCT06294860 id: 01C317 briefTitle: Biological Age in Children With GH Deficiency Undergoing Hormone Replacement Therapy acronym: ETABIOGHD overallStatus: RECRUITING date: 2023-06-19 date: 2024-12-31 date: 2024-12-31 date: 2024-03-06 date: 2024-03-12 name: Istituto Auxologico Italiano class: OTHER briefSummary: The primary objective of the study is to evaluate the epigenetic age in children with GH deficiency, before and after 6 months of treatment with growth hormone replacement therapy. The secondary objective is to correlate the epigenetic age with the auxometric and biochemical parameters used in the clinical-endocrinological practice. The results of the study will be useful to set up the clinical and biochemical follow-up of the hormone replacement therapy with rhGH and to understand the biomolecular mechanisms at the base of the debated "anti" or "pro" aging action of GH, the most important anabolic hormone of the human organism. conditions: Growth Hormone Deficiency conditions: Short Stature studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 12 type: ESTIMATED measure: Measurement of biological (epigenetic) age sex: ALL minimumAge: 5 Years maximumAge: 15 Years stdAges: CHILD facility: Istituto Auxologico Italiano status: RECRUITING city: Milano zip: 20145 country: Italy name: Alessandro Sartorio role: CONTACT phone: +390261911 phoneExt: 2426 email: sartorio@auxologico.it lat: 45.46427 lon: 9.18951 hasResults: False